ArticleClinical and experimental gastroenterology2009
Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
Article in Clinical and experimental gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
- Article
- A Comprehensive Review of Xanthan Gum-Based Oral Drug Delivery Systems.International journal of molecular sciences · 2024Review
- Rebuilding trust in proton pump inhibitor therapy.World journal of gastroenterology · 2022Review
- Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.Journal of neurogastroenterology and motility · 2018Review
- Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe.Clinical and experimental gastroenterology · 2018Article
- Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule.Therapeutic advances in gastroenterology · 2016Article
- Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole.Therapeutic advances in gastroenterology · 2016Article
- Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR.Therapeutics and clinical risk management · 2015Review
- The value of branded proton pump inhibitors: formulary considerations.P & T : a peer-reviewed journal for formulary management · 2011Article
- Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.Drugs · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although proton pump inhibitors (PPI) have a record of remarkable effectiveness and safety in the management of gastroesophageal reflux disease (GERD), several treatment challenges with PPI have emerged. Dexlansoprazole MR is the (R)-enantiomer of lansoprazole contained in a formulation that produces two distinct releases of drug and significantly extends the duration of active plasma concentrations and % time pH > 4 beyond that of conventional single-release PPI. Dexlansoprazole MR can be administered without regard to meals or the timing of meals in most patients. Dexlansoprazole MR 60 mg demonstrated similar efficacy for healing of erosive esophagitis at 8 weeks compared with lansoprazole 30 mg, and dexlansoprazole MR 30 mg was superior to placebo for maintenance of healed erosive esophagitis at 6 months with 99% of nights and 96% of days heartburn-free over 6 months in patients taking dexlansoprazole MR 30 mg. Superior relief of heartburn occurred in patients taking dexlansoprazole MR 30 mg (55% heartburn-free 24-hour periods) vs placebo (14%) for symptomatic nonerosive GERD. The safety profile of dexlansoprazole MR is similar to that of lansoprazole. The extended pharmacodynamic effects, added convenience, and efficacy and safety of dexlansoprazole MR offer a novel approach to gastric pH control in patients with acid-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.